Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Similar documents
Dyslipidemia. (Med-341)

Dyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Antihyperlipidemic Drugs

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

MOLINA HEALTHCARE OF CALIFORNIA

Antihyperlipidemic Drugs

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

Antihyperlipidemic drugs

Management of Post-transplant hyperlipidemia

Introduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)

Anti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

Fibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr

Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam

Pathophysiology of Lipid Disorders

B. Patient has not reached the percentage reduction goal with statin therapy

CLINICAL IMPORTANCE OF LIPOPROTEINS

MMBS, MMED (Path),MAACB, MACTM, MACRRM

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Drug regulation of serum lipids

Classification. Etiology

Lipids, lipoproteins and cardiovascular disease

10/1/2008. Therapy? Disclosure Statement

Lipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute

Learning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?

North Americans consume 100 g of fat per day on

A Review: Atherosclerosis & its treatment

Drugs for Dyslipidemias

Approach to Dyslipidemia among diabetic patients

Lipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

Southern Derbyshire Shared Care Pathology Guidelines. Dyslipidaemia

Chapter (5) Etiology of Low HDL- Cholesterol

PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL

DISLIPIDEMIA. Dharma Lindarto. Div: Endokrinologi-Metabolik. Departemen Ilmu Penyakit Dalam FK USU/RSUP. H Adam Malik Medan

Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology

Financial Disclosures

Lipid Lowering Drugs. Dr. Alia Shatanawi

STRUCTURE AND METABOLISM Of LIPIDS AND LIPOPROTEINS. R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

Imbalances in lipid components

Dyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Zuhier Awan, MD, PhD, FRCPC

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Lipids Testing

Lipids Testing

STATIN UTILIZATION MANAGEMENT CRITERIA

ATP IV: Predicting Guideline Updates

Dietary therapy for different forms of hyperlipoproteinemia

Chapter VIII: Dr. Sameh Sarray Hlaoui

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD

Arteriosclerosis & Atherosclerosis

Hyperlipidemia in Diabetes Mellitus:Pathogenesis, Diagnosis, and Pharmacological Therapy

hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER

Copy right protected Page 1

Lipid/Lipoprotein Structure and Metabolism (Overview)

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Dr G R Letchuman. Clogged by Cholesterol

determination of Triglyceride in Serum Amal Alamri

Topic 11. Coronary Artery Disease

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

A review on hyperlipidemia

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

Altered concentrations of blood plasma

CE Prn. Pharmacy Continuing Education from WF Professional Associates ABOUT WFPA LESSONS TOPICS ORDER CONTACT MCA EXAM REVIEWS

March 2005 Current Trends in Treating Elevated Cholesterol H01

Major recommendations for statin therapy for ASCVD prevention

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

International Journal of Chemistry and Pharmaceutical Sciences

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ

Laboratory Investigation of Dyslipidemia

Non-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016

Endorama By Anoopa Koshy, M.D.

Advances in Lipid Management

Lipoproteins Metabolism

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

PATIENT INFORMATION. Medicine To Treat: C ardiac Diseases. Lipid-Lowering Medicines. Statins Fibrates Fat Binding Agents Nicotinic Acid Group

High density lipoprotein metabolism

Index. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.

FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)

Dyslipidaemia. Dr NM Oosthuizen Dept of Chemical Pathology SA

CHOLESTEROL REDUCING MEDICATIONS. Five Main Categories. 1. Statins 2. Fibrates 3. Resins 4. Niacin 5. Cholesterol absorption inhibitor

In May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD

Management of Lipids in Primary and Secondary Prevention of Cardiovascular Diseases

Lipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels

Familial hypercholesterolaemia

Harms of treatment with cholesterol-lowering drugs in. children: A systematic review of the published literature

Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia


2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin

Lipid profile in Diabetes Mellitus

Transcription:

Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia Tests for Hyperlipidemia Whom to Screen for Dyslipidemia? Medications for Hyperlipidemia

The story of lipids Chylomicrons transport fats from the intestinal mucosa to the liver In the liver, the chylomicrons release triglycerides and some cholesterol and become low-density lipoproteins (LDL). LDL then carries fat and cholesterol to the body s cells. High-density lipoproteins (HDL) carry fat and cholesterol back to the liver for excretion.

When oxidized LDL cholesterol gets high, atheroma formation in the walls of arteries occurs, which causes atherosclerosis. HDL cholesterol is able to go and remove cholesterol from the atheroma. Atherogenic cholesterol LDL, VLDL, IDL Atherosclerosis

Definition Hyperlipidemia is defined as an elevation of one or more of the following: cholesterol, cholesterol esters, phospholipids, or triglycerides. Hyperlipoprotein emia describes an increased concentration of the lipoprotein macromolecules that transport lipids in the plasma.

Classification of hyperlipidemia Hyperlipidemias may basically be classified as either familial (also called primary) caused by specific genetic abnormalities, or acquired (also called secondary) when resulting from another underlying disorder that leads to alterations in plasma lipid and lipoprotein metabolism. Also, hyperlipidemia may be idiopathic, that is, without known cause.

Hyperlipidemias are also classified according to which types of lipids are elevated, that is hypercholesterolemia, hypertriglyceridemia or both in combined hyperlipidemia. Elevated levels of Lipoprotein(a) may also be classified as a form of hyperlipidemia. Relative prevalence of familial forms of hyperlipidemia

Hyperlipoproteinemia type I Type I hyperlipoproteinemia exists in several forms: Lipoprotein lipase deficiency (Type Ia), due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2, resulting in elevated chylomicrons, the particles that transfer fatty acids from the digestive tract to the liver. Familial apoprotein CII deficiency (Type Ib), a condition caused by a lack of lipoprotein lipase activator.

Type I hyperlipoproteinemia usually presents in childhood with eruptive xanthomata and abdominal colic. Complications include retinal vein occlusion, acute pancreatitis, steatosis and organomegaly, and lipaemia retinalis.

Acquired (secondary) Acquired hyperlipidemias (also called secondary dyslipoproteinemias) may result in increased risk of premature atherosclerosis or, when associated with marked hypertriglyceridemia, may lead to pancreatitis and other complications of the chylomicronemia syndrome. The most common causes of acquired hyperlipidemia are:

diabetes mellitus Use of drugs such as diuretics, beta blockers, and estrogens Other conditions leading to acquired hyperlipidemia include: Hypothyroidism renal failure nephrotic syndrome alcohol usage Some rare endocrine disorders and metabolic disorders

Tests Because hyperlipidemia usually doesn't cause symptoms, you will need a blood test for a diagnosis. The National Cholesterol Education Program recommends that people get this test every 5 years after age 20.

The physician will compare your results to established ranges. The ranges help the physician diagnose hyperlipidemia and then decide whether you will need lifestyle modification, medical treatment, or both as treatments. The physician will also determine whether you might have atherosclerosis or other risk factors for heart disease.

Most blood tests measure levels of LDL (sometimes called "bad") cholesterol, HDL (sometimes called "good") cholesterol, total cholesterol (LDL plus HDL), and triglycerides. To have a low risk of heart disease, your desirable lipid levels are: LDL less than 130 mg/dl HDL greater than 40 mg/dl (men) or 50 mg/dl (women) Total cholesterol less than 200 mg/dl Triglycerides less than 200 mg/dl

Medications for Hyperlipidemia Drug Class Agents Effects (% change) Side Effects HMG CoA reductase inhibitors Lovastatin Pravastatin LDL (18-55), HDL (5-15) Triglycerides (7-30) Myopathy, increased liver enzymes Cholesterol absorption inhibitor Ezetimibe LDL( 14-18), HDL (1-3) Triglyceride (2) Headache, GI distress Nicotinic Acid LDL (15-30), HDL (15-35) Triglyceride (20-50) Flushing, Hyperglycemia, Hyperuricemia, GI distress, hepatotoxicity Fibric Acids Gemfibrozil Fenofibrate LDL (5-20), HDL (10-20) Triglyceride (20-50) Dyspepsia, gallstones, myopathy Bile Acid sequestrants Cholestyramine LDL HDL No change in triglycerides GI distress, constipation, decreased absorption of other drugs

Whom to Screen for Dyslipidemia? Influenced by cardiac risk factors: By age alone: Men over age 40 Women over age 50 (or post-menopausal) Other risk factors (at any age): DM, HTN, Smoking, Abdominal Obesity Family history of early cardiovascular disease Physical signs of hyperlipidemia (at any age): Xanthomata, xanthelasmas, arcus corneae, etc Evidence of existing atherosclerosis (at any age)

Manifestations of Dyslipidemia Eruptive xanthomata on the forearm of a patient with severe TGs Xanthelasma s and tendon xanthomata in patients with severe LDL (the patient at the bottom has heterozygou s familial hypercholesterolemia)